000			02008nam a2200481 i 4500
999			_c283726 _d283726
001			on1108336837
003			OCoLC
005			20190823195150.0
006			m o d f
007			cr bn||||a||||
008			190712s2019 dcu o f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1008-I (online)
086	0		_aY 1.1/8:116-48
099			_aY 1.1/8:116-48
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce,
245	1	0	_aPurple Book Continuity Act of 2019 : _breport (to accompany H.R. 1520) (including cost estimate of the Congressional Budget Office).
264		1	_a[Washington, D.C.] : _b[U.S. Government Publishing Office], _c[2019]
300			_a1 online resource (23 pages)
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
490	1		_aReport / 116th Congress, 1st session, House of Representatives ; _v116-46
500			_a"May 3, 2019."
500			_aTitle from caption.
500			_aCRDP Program record.
588			_aDescription based on online resource, PDF version; title from title page (govinfo, viewed July 12, 2019).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Energy and Commerce. _tPurple Book Continuity Act of 2019 _w(OCoLC)1101904321
810	1		_aUnited States. _bCongress. _bHouse. _tReport ; _v116-48.
856	4	0	_3PDF version _uhttps://purl.fdlp.gov/GPO/gpo123044
856	4	0	_3Text version _uhttps://purl.fdlp.gov/GPO/gpo123047
050		4	_aKF32 _b.E55 2019f
650		0	_aBiological products _zUnited States.
650		0	_aBiological products _zUnited States _xSafety measures.
650		0	_aDrug approval _zUnited States.
650		0	_aPatent laws and legislation _zUnited States.
650		0	_aDrugs _zUnited States _xPatents.
650		0	_aDrugs _xPrices _zUnited States.
655		7	_aLegislative materials. _2lcgft
942			_2sudocs _c8